Progression of hepatic neoplasms is severely retarded in mice lacking the bisecting N-acetylglucosamine on N-glycans

Evidence for a glycoprotein factor that facilitates hepatic tumor progression

Mantu Bhaumik, Thomas M. Harris, Subha Sundaram, Linda Johnson, Joseph Guttenplan, Charles Rogler, Pamela Stanley

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The glycosyltransferase termed GlcNAc-TIII is dedicated to the transfer of a single N-acetylglucosamine (GlcNAc) residue (the bisecting GlcNAc), to a subset of N-glycans in glycoproteins. The addition of this GlcNAc is differentially regulated during development and is induced in certain cancers, particularly in hepatic tumorigenesis. To investigate a functional role for the bisecting GlcNAc in the development of liver cancer, the Mgat3 gene that cedes for GlcNAc-TIII, was inactivated by targeted gene disruption, and the susceptibility of Mgat3(-/-) mice to tumor induction was tested. After a single injection with diethylnitrosamine and subsequent treatment with phenobarbitol for 6 months, Mgat3(+/+) and Mgat3(+/-) mice had grossly enlarged livers that contained numerous tumors. By stark contrast, Mgat3(-/- ) mice had livers of normal size, and only 50% of mice had one to four small tumors. However, histological examination showed that Mgat3(-/-) livers had significant numbers of basophilic foci, and by 10-12 months after diethylnitrosamine injection, tumors had developed in Mgat3(-/-) mice. Therefore, initiation occurred in Mgat3(-/-) mice but progression was severely retarded. Assays for Mgat3 gene expression in tumor tissue gave an unexpected result. In contrast to the situation in the rat, hepatic tumor formation in the mouse was not accompanied by a dramatic increase of GlcNAc- TIII activity nor of glycoproteins with a bisecting GlcNAc, nor of Mgat3 gene expression in tumor tissue from wild-type mice. The data suggest that a glycoprotein factor with the bisecting GlcNAc facilitates tumor progression in liver. In the absence of the bisecting GlcNAc in Mgat3(-/-) mice, the factor is reduced in activity, and tumor progression is severely retarded.

Original languageEnglish (US)
Pages (from-to)2881-2887
Number of pages7
JournalCancer Research
Volume58
Issue number13
StatePublished - Jul 1 1998

Fingerprint

Acetylglucosamine
Liver Neoplasms
Polysaccharides
Glycoproteins
Liver
Neoplasms
Diethylnitrosamine
Gene Expression
Glycosyltransferases
Injections
Hepatomegaly
Neoplasm Genes
Carcinogenesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Progression of hepatic neoplasms is severely retarded in mice lacking the bisecting N-acetylglucosamine on N-glycans : Evidence for a glycoprotein factor that facilitates hepatic tumor progression. / Bhaumik, Mantu; Harris, Thomas M.; Sundaram, Subha; Johnson, Linda; Guttenplan, Joseph; Rogler, Charles; Stanley, Pamela.

In: Cancer Research, Vol. 58, No. 13, 01.07.1998, p. 2881-2887.

Research output: Contribution to journalArticle

@article{7a2af7a6952c4b9fb11b79cffd0881ea,
title = "Progression of hepatic neoplasms is severely retarded in mice lacking the bisecting N-acetylglucosamine on N-glycans: Evidence for a glycoprotein factor that facilitates hepatic tumor progression",
abstract = "The glycosyltransferase termed GlcNAc-TIII is dedicated to the transfer of a single N-acetylglucosamine (GlcNAc) residue (the bisecting GlcNAc), to a subset of N-glycans in glycoproteins. The addition of this GlcNAc is differentially regulated during development and is induced in certain cancers, particularly in hepatic tumorigenesis. To investigate a functional role for the bisecting GlcNAc in the development of liver cancer, the Mgat3 gene that cedes for GlcNAc-TIII, was inactivated by targeted gene disruption, and the susceptibility of Mgat3(-/-) mice to tumor induction was tested. After a single injection with diethylnitrosamine and subsequent treatment with phenobarbitol for 6 months, Mgat3(+/+) and Mgat3(+/-) mice had grossly enlarged livers that contained numerous tumors. By stark contrast, Mgat3(-/- ) mice had livers of normal size, and only 50{\%} of mice had one to four small tumors. However, histological examination showed that Mgat3(-/-) livers had significant numbers of basophilic foci, and by 10-12 months after diethylnitrosamine injection, tumors had developed in Mgat3(-/-) mice. Therefore, initiation occurred in Mgat3(-/-) mice but progression was severely retarded. Assays for Mgat3 gene expression in tumor tissue gave an unexpected result. In contrast to the situation in the rat, hepatic tumor formation in the mouse was not accompanied by a dramatic increase of GlcNAc- TIII activity nor of glycoproteins with a bisecting GlcNAc, nor of Mgat3 gene expression in tumor tissue from wild-type mice. The data suggest that a glycoprotein factor with the bisecting GlcNAc facilitates tumor progression in liver. In the absence of the bisecting GlcNAc in Mgat3(-/-) mice, the factor is reduced in activity, and tumor progression is severely retarded.",
author = "Mantu Bhaumik and Harris, {Thomas M.} and Subha Sundaram and Linda Johnson and Joseph Guttenplan and Charles Rogler and Pamela Stanley",
year = "1998",
month = "7",
day = "1",
language = "English (US)",
volume = "58",
pages = "2881--2887",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Progression of hepatic neoplasms is severely retarded in mice lacking the bisecting N-acetylglucosamine on N-glycans

T2 - Evidence for a glycoprotein factor that facilitates hepatic tumor progression

AU - Bhaumik, Mantu

AU - Harris, Thomas M.

AU - Sundaram, Subha

AU - Johnson, Linda

AU - Guttenplan, Joseph

AU - Rogler, Charles

AU - Stanley, Pamela

PY - 1998/7/1

Y1 - 1998/7/1

N2 - The glycosyltransferase termed GlcNAc-TIII is dedicated to the transfer of a single N-acetylglucosamine (GlcNAc) residue (the bisecting GlcNAc), to a subset of N-glycans in glycoproteins. The addition of this GlcNAc is differentially regulated during development and is induced in certain cancers, particularly in hepatic tumorigenesis. To investigate a functional role for the bisecting GlcNAc in the development of liver cancer, the Mgat3 gene that cedes for GlcNAc-TIII, was inactivated by targeted gene disruption, and the susceptibility of Mgat3(-/-) mice to tumor induction was tested. After a single injection with diethylnitrosamine and subsequent treatment with phenobarbitol for 6 months, Mgat3(+/+) and Mgat3(+/-) mice had grossly enlarged livers that contained numerous tumors. By stark contrast, Mgat3(-/- ) mice had livers of normal size, and only 50% of mice had one to four small tumors. However, histological examination showed that Mgat3(-/-) livers had significant numbers of basophilic foci, and by 10-12 months after diethylnitrosamine injection, tumors had developed in Mgat3(-/-) mice. Therefore, initiation occurred in Mgat3(-/-) mice but progression was severely retarded. Assays for Mgat3 gene expression in tumor tissue gave an unexpected result. In contrast to the situation in the rat, hepatic tumor formation in the mouse was not accompanied by a dramatic increase of GlcNAc- TIII activity nor of glycoproteins with a bisecting GlcNAc, nor of Mgat3 gene expression in tumor tissue from wild-type mice. The data suggest that a glycoprotein factor with the bisecting GlcNAc facilitates tumor progression in liver. In the absence of the bisecting GlcNAc in Mgat3(-/-) mice, the factor is reduced in activity, and tumor progression is severely retarded.

AB - The glycosyltransferase termed GlcNAc-TIII is dedicated to the transfer of a single N-acetylglucosamine (GlcNAc) residue (the bisecting GlcNAc), to a subset of N-glycans in glycoproteins. The addition of this GlcNAc is differentially regulated during development and is induced in certain cancers, particularly in hepatic tumorigenesis. To investigate a functional role for the bisecting GlcNAc in the development of liver cancer, the Mgat3 gene that cedes for GlcNAc-TIII, was inactivated by targeted gene disruption, and the susceptibility of Mgat3(-/-) mice to tumor induction was tested. After a single injection with diethylnitrosamine and subsequent treatment with phenobarbitol for 6 months, Mgat3(+/+) and Mgat3(+/-) mice had grossly enlarged livers that contained numerous tumors. By stark contrast, Mgat3(-/- ) mice had livers of normal size, and only 50% of mice had one to four small tumors. However, histological examination showed that Mgat3(-/-) livers had significant numbers of basophilic foci, and by 10-12 months after diethylnitrosamine injection, tumors had developed in Mgat3(-/-) mice. Therefore, initiation occurred in Mgat3(-/-) mice but progression was severely retarded. Assays for Mgat3 gene expression in tumor tissue gave an unexpected result. In contrast to the situation in the rat, hepatic tumor formation in the mouse was not accompanied by a dramatic increase of GlcNAc- TIII activity nor of glycoproteins with a bisecting GlcNAc, nor of Mgat3 gene expression in tumor tissue from wild-type mice. The data suggest that a glycoprotein factor with the bisecting GlcNAc facilitates tumor progression in liver. In the absence of the bisecting GlcNAc in Mgat3(-/-) mice, the factor is reduced in activity, and tumor progression is severely retarded.

UR - http://www.scopus.com/inward/record.url?scp=0032126529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032126529&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 2881

EP - 2887

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 13

ER -